Merck & Co.

Alzheimer's Disease Diagnostics and Therapeutics Market - Global Growth, Trends, and Forecasts Report 2020-2025 - ResearchAndMarkets.com

Friday, January 15, 2021 - 2:12pm

The "Alzheimer's Disease Diagnostics and Therapeutics Market - Growth, Trends, and Forecasts (2020 - 2025)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Alzheimer's Disease Diagnostics and Therapeutics Market - Growth, Trends, and Forecasts (2020 - 2025)" report has been added to ResearchAndMarkets.com's offering.
  • The development of clinical diagnostics and therapeutics for Alzheimer's disease (AD) and other neurodegenerative conditions is becoming very important.
  • The United States holds the largest share of the global Alzheimer's disease diagnostics and therapeutics market.
  • Companies, like F. Hoffmann-La Roche, Novartis AG, Merck & Co., Pfizer Inc., and Eli Lily & Co., hold a substantial market share in the Alzheimer's disease diagnostics and therapeutics market.

José M. Vega, M.D. Joins Moderna as Chief Safety Officer

Tuesday, January 12, 2021 - 1:00pm

joined Moderna as Chief Safety Officer effective Monday, January 11, 2021.

Key Points: 
  • joined Moderna as Chief Safety Officer effective Monday, January 11, 2021.
  • I am thrilled to welcome Jos to the Moderna team as we enter the next phase of growth of our company.
  • Dr. Vega joins Moderna from Merck (NYSE: MRK) where he led the Global Clinical Safety and Pharmacovigilance organization and served as the Chief Safety Officer for Merck Research Laboratories (MRL) since 2013.
  • In this role, he led a global team of nearly 600 safety and pharmacovigilance professionals in Clinical Safety Risk Management, Medical Safety Review, Global Pharmacovigilance, and the EU Qualified Person for Pharmacovigilance (QPPV) groups.

Eisai to Present Abstracts on Lenvatinib at 2021 Gastrointestinal Cancers Symposium

Tuesday, January 12, 2021 - 3:37am

TOKYO, Jan 12, 2021 - (JCN Newswire) - Eisai Co., Ltd. has announced that presentations on a series of abstracts highlighting updates on its in-house discovered lenvatinib mesylate (product name: LENVIMA, the orally available kinase inhibitor, "lenvatinib") will be given at the Gastrointestinal Cancers Symposium Virtual Meeting, from January 15 to 17, 2021.

Key Points: 
  • TOKYO, Jan 12, 2021 - (JCN Newswire) - Eisai Co., Ltd. has announced that presentations on a series of abstracts highlighting updates on its in-house discovered lenvatinib mesylate (product name: LENVIMA, the orally available kinase inhibitor, "lenvatinib") will be given at the Gastrointestinal Cancers Symposium Virtual Meeting, from January 15 to 17, 2021.
  • In March 2018, Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A., through an affiliate, entered into a strategic collaboration for the worldwide co-development and co-commercialization of lenvatinib.
  • Eisai positions oncology as a key therapeutic area, and is aiming to discover revolutionary new medicines with the potential to cure cancer.
  • Eisai aspires to discover innovative new drugs with new targets and mechanisms of action from these Ricchi, with the aim of contributing to the cure of cancers.

Global Active Pharmaceutical Ingredient (API) Market Analysis 2020 with Company Profiles of Leading Players Including Roche Holding AG, Pfizer Inc, Merck & Co. and More

Monday, January 11, 2021 - 12:00pm

The global API market is forecasted to reach US$270.83 billion in 2024, growing at a CAGR of 6.5% for the period spanning 2020-2024.

Key Points: 
  • The global API market is forecasted to reach US$270.83 billion in 2024, growing at a CAGR of 6.5% for the period spanning 2020-2024.
  • The factors such as increasing ageing population, rising healthcare expenditure per capita, growing cancer patients, inclining orphan drugs industry and accelerating outsourcing of API drugs are expected to drive the market.
  • The report provides a comprehensive analysis of the global API market, segmented by synthesis (biological & small molecule) and manufacturers (captive & merchant).
  • The competitive landscape of the market, along with the company profiles of leading players (Roche Holding AG, Pfizer Inc., Novartis AG, Merck & Co., Inc., Bristol-Myers Squibb Company and Teva Pharmaceutical Industries Limited) are also presented in detail.

Symvivo Corporation Announces Collaboration with Merck

Tuesday, January 5, 2021 - 2:00pm

Symvivo Corporation, a clinical-stage biotechnology company advancing a proprietary bacTRL gene delivery platform, announced today that it has entered into a research collaboration with Merck Sharp and Dohme Corp.

Key Points: 
  • Symvivo Corporation, a clinical-stage biotechnology company advancing a proprietary bacTRL gene delivery platform, announced today that it has entered into a research collaboration with Merck Sharp and Dohme Corp.
  • Under the terms of the agreement, Merck receives an option to take an exclusive license to Symvivos bacTRL platform technology for use in advancing delivery of oral vaccines.
  • We are excited to be collaborating with Merck on this novel program, said Lloyd Mackenzie, President and Chief Operating Officer at Symvivo.
  • Symvivo is a clinical-stage biotechnology company advancing a proprietary platform for the site-specific delivery of genes for the treatment and prevention of life-threatening diseases.

Aura Biosciences Appoints David Johnson to Its Board of Directors

Tuesday, January 5, 2021 - 12:00pm

Aura Biosciences, a clinical-stage oncology company developing a novel class of drug conjugate therapies for multiple oncology indications, today announced the appointment of David Johnson to its Board of Directors.

Key Points: 
  • Aura Biosciences, a clinical-stage oncology company developing a novel class of drug conjugate therapies for multiple oncology indications, today announced the appointment of David Johnson to its Board of Directors.
  • In the last few years, David has led several biopharma transactions, including the acquisition of VelosBio by Merck for $2.75 billion.
  • I am excited to be joining Auras Board of Directors during such an important period of growth for the Company, said Mr. Johnson.
  • In addition to Auras Board, Mr. Johnson serves on the Bord of Directors of Zentalis Pharmaceuticals, a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers.

Merck to Present at the 39th Annual J.P. Morgan Healthcare Conference

Monday, January 4, 2021 - 11:45am

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that Kenneth C. Frazier, chairman and chief executive officer, Robert Davis, chief financial officer, and Dr. Dean Li, president, Merck Research Laboratories, are scheduled to participate in the 39th Annual J.P. Morgan Healthcare Conference on Jan. 11, 2021 at 4:30 p.m. EST.

Key Points: 
  • Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that Kenneth C. Frazier, chairman and chief executive officer, Robert Davis, chief financial officer, and Dr. Dean Li, president, Merck Research Laboratories, are scheduled to participate in the 39th Annual J.P. Morgan Healthcare Conference on Jan. 11, 2021 at 4:30 p.m. EST.
  • We demonstrate our commitment to patients and population health by increasing access to health care through far-reaching policies, programs and partnerships.
  • Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA
    This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the company) includes forward-looking statements within the meaning of the safe harbor provisions of the U.S.
  • These statements are based upon the current beliefs and expectations of the companys management and are subject to significant risks and uncertainties.

A2 Biotherapeutics Enters Into Collaboration Agreement With Merck to Develop Allogeneic Cell Therapy for Solid Tumor Cancers

Wednesday, December 23, 2020 - 3:07pm

Merck will assist with preclinical development and has the option to exclusively develop, manufacture and commercialize the candidate following Phase 1.

Key Points: 
  • Merck will assist with preclinical development and has the option to exclusively develop, manufacture and commercialize the candidate following Phase 1.
  • In vitro studies have provided compelling evidence supporting the view that Tmod-based cell therapy can distinguish tumor cells from normal cells, across multiple tumor targets, said Dr. Roger M. Perlmutter, President, Merck Research Laboratories.
  • A2 anticipates that the successful development of its allogeneic Tmod candidate therapy will enable subsequently developed allogeneic Tmod candidates.
  • A2 Biotherapeutics is using its next-generation cell therapy Tmod platform to revolutionize the treatment of solid tumor cancers.

HitGen Announces License Agreement With Merck & Co., Inc., Kenilworth, NJ USA to Access Compounds for Potential Development of a Novel Class of Drugs

Monday, December 21, 2020 - 1:31pm

Several novel small molecule lead series with novel profiles for an undisclosed target nominated by Merck & Co., Inc Kenilworth, NJ USA are the subject of this license.

Key Points: 
  • Several novel small molecule lead series with novel profiles for an undisclosed target nominated by Merck & Co., Inc Kenilworth, NJ USA are the subject of this license.
  • Under the terms of the collaboration agreement, HitGen will grant exclusive rights to Merck & Co., Inc Kenilworth, NJ USA to develop and commercialize the licensed compounds.
  • HitGen will be eligible for preclinical and clinical milestone payments as the project progresses, in addition to a license fee.
  • Todays announcement marks another significant milestone in the long-lasting collaboration between Merck & Co., Inc Kenilworth, NJ USA and HitGen initiated in 2016 and expanded in 2018.

Completion of sale of VelosBio

Friday, December 18, 2020 - 3:07pm

The issuer is solely responsible for the content of this announcement.

Key Points: 
  • The issuer is solely responsible for the content of this announcement.
  • LONDON, 18 December 2020: Arix Bioscience plc ("Arix", LSE: ARIX), a global venture capital company focused on investing in and building breakthrough biotech companies, today announces the completion of the previously announced sale of its portfolio company VelosBio Inc. ("VelosBio"), to Merck & Co., Inc., Kenilworth NJ., USA, for final all cash consideration of $2.75 billion.
  • The trade sale of VelosBio generates gross proceeds of $187.0 million (138.5 million) [1] to Arix, representing a 12.5x return on its original investment of $15.0 million (11.8 million) and an internal rate of return (IRR) of 328%.
  • The tax treatment of this transaction will be detailed within Arix's 2020 Annual Report and Accounts, to be published in March 2021.